EHA 2017 | Understanding biosimilars
Bertrand Coiffier, MD from the Centre Hospitalier Lyon-Sud, Pierre-Bénite, France talks about the recent research developments and the increased understanding of biosimilars at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain. Only over the past few years, due to the introduction of various trials, have more physicians gained a better understanding of what biosimilars are, and are able to appreciate that biosimilars have the same safety and efficacy ratios compared to their originators. Prof. Coiffier provides examples of disease areas where biosimilars are already in use and he expects that they will become more accepted in hematology in the future.
Get great new content delivered to your inboxSign up